130 related articles for article (PubMed ID: 28429358)
1. SLPI promotes the gastric cancer growth and metastasis by regulating the expression of P53, Bcl-2 and Caspase-8.
Du XY; Liu X; Wang ZJ; Wang YY
Eur Rev Med Pharmacol Sci; 2017 Apr; 21(7):1495-1501. PubMed ID: 28429358
[TBL] [Abstract][Full Text] [Related]
2. Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells.
Choi BD; Jeong SJ; Wang G; Park JJ; Lim DS; Kim BH; Cho YI; Kim CS; Jeong MJ
Int J Mol Med; 2011 Oct; 28(4):527-34. PubMed ID: 21687932
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer.
Cheng WL; Wang CS; Huang YH; Liang Y; Lin PY; Hsueh C; Wu YC; Chen WJ; Yu CJ; Lin SR; Lin KH
Int J Cancer; 2008 Oct; 123(8):1787-96. PubMed ID: 18688858
[TBL] [Abstract][Full Text] [Related]
4. M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signaling pathways.
Wang Y; Xiao H; Wang C; Wu H; He H; Yao C; Cui J; Li W
J Cell Biochem; 2020 Mar; 121(3):2330-2342. PubMed ID: 31692032
[TBL] [Abstract][Full Text] [Related]
5. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.
Sugino T; Yamaguchi T; Ogura G; Kusakabe T; Goodison S; Homma Y; Suzuki T
J Pathol; 2007 Jun; 212(2):152-60. PubMed ID: 17455170
[TBL] [Abstract][Full Text] [Related]
6. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.
Ji Q; Hao X; Meng Y; Zhang M; Desano J; Fan D; Xu L
BMC Cancer; 2008 Sep; 8():266. PubMed ID: 18803879
[TBL] [Abstract][Full Text] [Related]
7. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway.
Wei GH; Wang X
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3850-3856. PubMed ID: 28975980
[TBL] [Abstract][Full Text] [Related]
8. The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.
Xie W; Zhang H; Qin S; Zhang J; Fan X; Yin Y; Liang R; Long H; Yi W; Fu D; Ma C; Lv M; Yu F
Gene; 2019 Dec; 720():144088. PubMed ID: 31476404
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Bcl-2 and p53 expression in gastric cancer.
Lee HK; Lee HS; Yang HK; Kim WH; Lee KU; Choe KJ; Kim JP
Int J Colorectal Dis; 2003 Nov; 18(6):518-25. PubMed ID: 12811476
[TBL] [Abstract][Full Text] [Related]
10. Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.
Nakamura K; Takamoto N; Hongo A; Kodama J; Abrzua F; Nasu Y; Kumon H; Hiramatsu Y
Oncol Rep; 2008 May; 19(5):1085-91. PubMed ID: 18425362
[TBL] [Abstract][Full Text] [Related]
11. Human uterus myoma and gene expression profiling: A novel in vitro model for studying secretory leukocyte protease inhibitor-mediated tumor invasion.
Mikami Y; Fukushima A; Komiyama Y; Iwase T; Tsuda H; Higuchi Y; Hayakawa S; Kuyama K; Komiyama K
Cancer Lett; 2016 Aug; 379(1):84-93. PubMed ID: 27238568
[TBL] [Abstract][Full Text] [Related]
12. Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma.
Wang X; Jin Y; Li YX; Yang Y
Oncol Rep; 2018 Apr; 39(4):1793-1804. PubMed ID: 29436667
[TBL] [Abstract][Full Text] [Related]
13. Secretory Leukocyte Protease Inhibitor (SLPI) expression downregulates E-cadherin, induces β-catenin re-localisation and triggers apoptosis-related events in breast cancer cells.
Rosso M; Lapyckyj L; Amiano N; Besso MJ; Sánchez M; Chuluyan E; Vazquez-Levin MH
Biol Cell; 2014 Sep; 106(9):308-22. PubMed ID: 25039920
[TBL] [Abstract][Full Text] [Related]
14. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
Wen J; Nikitakis NG; Chaisuparat R; Greenwell-Wild T; Gliozzi M; Jin W; Adli A; Moutsopoulos N; Wu T; Warburton G; Wahl SM
Am J Pathol; 2011 Jun; 178(6):2866-78. PubMed ID: 21641406
[TBL] [Abstract][Full Text] [Related]
15. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
Simpkins FA; Devoogdt NM; Rasool N; Tchabo NE; Alejandro EU; Kamrava MM; Kohn EC
Carcinogenesis; 2008 Mar; 29(3):466-72. PubMed ID: 17916899
[TBL] [Abstract][Full Text] [Related]
16. Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells.
Zuo J; Zhang C; Ren C; Pang D; Li Y; Xie X; Tang Z; Jiang X
Clin Transl Oncol; 2015 Apr; 17(4):314-21. PubMed ID: 25319722
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.
Devoogdt N; Rasool N; Hoskins E; Simpkins F; Tchabo N; Kohn EC
Cancer Sci; 2009 Mar; 100(3):434-40. PubMed ID: 19154415
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA‑34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET.
Wei B; Huang QY; Huang SR; Mai W; Zhong XG
Mol Med Rep; 2015 Oct; 12(4):5255-61. PubMed ID: 26238271
[TBL] [Abstract][Full Text] [Related]
19. Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.
Sayers KT; Brooks AD; Sayers TJ; Chertov O
PLoS One; 2014; 9(8):e104223. PubMed ID: 25110884
[TBL] [Abstract][Full Text] [Related]
20. Upregulated Vav2 in gastric cancer tissues promotes tumor invasion and metastasis.
Tan BB; Li Y; Fan LQ; Zhao Q; Liu QW; Liu Y; Wang D; Jia N
Tumour Biol; 2017 May; 39(5):1010428317698392. PubMed ID: 28459214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
